Free tool
FAERS Monitor: Cystadrops
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211302 or its brand name (Cystadrops, Cysteamine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
240
Serious
157
65% of reports
Hospitalization
96
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation41
- eye pain26
- death15
- vision blurred14
- vomiting14
- ocular hyperaemia13
- off label use9
- amino acid level increased8
- corneal neovascularisation8
- pneumonia8
- treatment noncompliance8
- dehydration7
- diarrhoea7
- inappropriate schedule of product administration7
- photophobia7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 21 |
| 2021 | 40 |
| 2022 | 40 |
| 2023 | 47 |
| 2024 | 57 |
| 2025 | 18 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,919 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| corneal neovascularisationSignal | 8 | 2936.4 | 1468.4 | 19,963 |
| amino acid level increasedSignal | 8 | 954.8 | 481.3 | 6,627 |
| eye irritationSignal | 41 | 62.5 | 47.3 | 2,424 |
| eye painSignal | 26 | 40.4 | 28.1 | 962 |
| photophobiaSignal | 7 | 32.6 | 15.7 | 184 |
| ocular hyperaemiaSignal | 13 | 24.0 | 14.2 | 265 |
| treatment noncomplianceSignal | 8 | 12.8 | 6.5 | 76 |
| vision blurredSignal | 14 | 8.9 | 5.4 | 91 |
| dehydrationSignal | 7 | 4.6 | 2.2 | 16 |
| inappropriate schedule of product administrationSignal | 7 | 3.4 | 1.6 | 10 |
| vomitingSignal | 14 | 2.6 | 1.6 | 13 |
| pneumonia | 8 | 2.2 | 1.1 | 4 |
| death | 15 | 1.5 | 0.9 | 2 |
| diarrhoea | 7 | 1.0 | 0.5 | 0 |
| off label use | 9 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.